Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.

Read more
Anchorage recreational marijuana sales a bullish indicator of Alaska’s growing market

Recreational marijuana sales in Alaska’s largest city continued to grow in 2020 despite the COVID-19 pandemic, highlighting the resiliency of the state’s adult-use industry even in challenging conditions.

Read more
Canada Will Let Health Care Professionals Legally Use Psychedelic Mushrooms, Health Minister Says

Canada will allow a handful of health care professionals to possess and consume psilocybin mushrooms in order to better treat the growing number of patients now permitted to use the psychedelic drug, the country’s top health official revealed in a recent interview.

Read more

Read more
Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

Entheon discusses its new strategic investment in Wonder Scientific.

Read more
USDA Expands Hemp Insurance Program

The U.S. Department of Agriculture has expanded its pilot Multi-Peril Crop Insurance plan for the hemp industry into new states and counties and announced improvements to the insurance.

Read more
BREAKING: U.S. House Votes to Legalize Cannabis Federally

Lawmakers in the U.S. House of Representatives today passed the Marijuana Opportunities, Reinvestment, and Expungement (MORE) Act in a mostly partisan 228-164 vote.

Read more
Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021

Entheon announces an agreement for the purpose of conducting a Phase 1 clinical trial.

Read more
BIG Psychedelics Financings Powering Future Investor Profits

Nearly half a billion dollars has recently flooded into the coffers of psychedelic drug companies. That’s enough capital to power a lot of growth.

Read more
BIG Financings Powering Future Profits in Psychedelic Stocks

Nearly $400 million dollars has recently flooded into the coffers of psychedelic drug companies. That’s enough capital to power a lot of growth.

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )